Evidence map›Paper›PMID 40298264›Full record

ArticleJournal of water and health2025

A comprehensive One Health investigation of erythromycin and quinupristin/dalfopristin resistant

Fereshteh Hasanpour, Farzad Khademi, Behnam Mohammadi Ghalehbin, Malek Namaki Kheljan, Elham Jannati, Sohrab Iranpour, Mohsen Arzanlou

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of water and health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fereshteh HasanpourDepartment of Microbiology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.
Farzad KhademiDepartment of Microbiology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.
Behnam Mohammadi GhalehbinZoonoses Research Center, Ardabil University of Medical Sciences, Ardabil, Iran; Department of Parasitology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.
Malek Namaki KheljanDepartment of Microbiology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.
Elham JannatiDepartment of Microbiology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.
Sohrab IranpourDepartment of Community Medicine, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.
Mohsen ArzanlouDepartment of Microbiology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran; Zoonoses Research Center, Ardabil University of Medical Sciences, Ardabil, Iran E-mail: m.arzanlou@arums.ac.ir; arzanlo53@gmail.com.ORCID https://orcid.org/0000-0002-4233-9497

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enterococci, flagged by the WHO as a rising cause of antibiotic-resistant infections, make surveillance crucial to control resistant strains. We investigated the resistance to linezolid, quinupristin/dalfopristin (Q/D), and erythromycin in

Indexed as

Anti-Bacterial AgentsDrug Resistance, BacterialEnterococcusEnterococcus faecalisEnterococcus faeciumErythromycinOne HealthVirginiamycinAnimalsGram-Positive Bacterial InfectionsHumansIranMicrobial Sensitivity TestsWastewaterAnti-Bacterial AgentsErythromycinquinupristin-dalfopristinVirginiamycinWastewaterantibiotic resistanceerythromycinlinezolidquinupristin/dalfopristin (Q/D)

Identifiers

PMID40298264

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.